Podcasts about treatment decisions

Learn how your treatment plan is decided and terms you may seeWe continue our series to help you understand cancer and its treatment. This week we focus on surgery, the oldest form of cancer treatment. Learn about surgery timing, types of cancer surgery, and how NCCN evidence-based guidelines provide a standard treatment path no matter where you are.In this Episode:02:58 - Wisconsin-Cheese, UFOs, and Booyah Stew04:52 - Anna Quindlen: Get a Life Where You Are Generous"08:06 - Medical Specialists Involved in Cancer Care08:52 - Treatment Decisions, Tumor Board and NCCN Guidelines12:03 - Adjuvant and Neoadjuvant Therapy13:13 - Surgery Timing, Reasons and Types18:00 - Discussion - NCCN and Role of Research24:34 - Reeves Keyworth:“On Loved Ones Telling the Dying to ‘Let Go”23:54 - OutroSurgery, radiation therapy, and chemotherapy alone or in combination are the most-common methods used to treat cancer. Specific treatment varies depending on the kind of cancer, the extent of the disease, its rate of progression, and the condition of the person. Surgery alone may not result in a cure and often chemotherapy and/or radiation are needed after surgery. Learn all about surgery and the guidelines your doctor will be following for your treatment.Support the showGet show notes and resources at our website: every1dies.org. Facebook | Instagram | YouTube | mail@every1dies.org

Why “What Do You Need from Me?” Should be Among the First Things We SayWhen someone with serious illness needs to make a decision about treatment, is facing the end of their life, or grieving the death of a loved one, it's easy to feel like you just don't know what to say. Learn conversational tools to help them more effectively. https://bit.ly/42hWWEw#friendship #grieving #whattosay #comfort #howtohelp #treatmentdecisions #dyingfriend #cancer #support #communication #listening #activelistening #seenheardunderstood #HUA In this Episode:04:23 – Iowa Road Trip and Recipe of the Week06:44 – “Get a Life, A Real Life” – Excerpt by Anna Quindlen 09:15 – How to See, Hear and Understand in Our Relationships17:21 – Honoring the Life of Hurricane, the most decorated K-9 officer in US history 19:23 – OutroRelated Podcasts:S3E18: What to Say to People Who are GrievingHow Do You Comfort a Dying Loved One?S4E5: How to Write a Condolence NoteS4E1: How to Share the News of a Death with Someone who has DementiaS5E6: Mothers and Their Daughters, A Blessing and a CurseS3E1: What you can do to help a grieving petS5E3: Grief Groceries – Care Packages for the BereavedS3E14: 15 Ways to Help a Grieving ChildS1E19: Helping children with loss of a grandparent – with Tracy HardingSupport the showGet show notes and resources at our website: every1dies.org. Facebook | Instagram | YouTube | mail@every1dies.org

Dr. Brooke Britton joins James Jacobson to demystify the mitotic index—a critical factor in understanding your dog's cancer diagnosis. Learn how this number, derived from a tumor biopsy, influences treatment decisions and prognosis for various types of dog cancers like mast cell tumors, soft tissue sarcomas, and melanomas. Dr. Britton shares her expertise in interpreting pathology reports and navigating the nuances of cancer care for your beloved pet. Topics Covered:  What is the mitotic index?  How pathologists calculate and report mitotic index.  When mitotic index is critical for treatment decisions.  The role of biopsies in cancer diagnosis and care.  Why tumors behave unpredictably and what that means for your dog.  Key Takeaway:  The mitotic index is just one of many factors in dog cancer care, but it can play a vital role in understanding tumor behavior and guiding treatment.  Your Voice Matters!   If you have a question for our team, or if you want to share your own hopeful dog cancer story, we want to hear from you! Go to https://www.dogcancer.com/ask to submit your question or story, or call our Listener Line at +1 808-868-3200 to leave a question.   Related Links:  An article on mitotic index: https://www.dogcancer.com/articles/diagnosis-and-medical-procedures/mitotic-index/  Chapters:  00:00 Introduction  00:30 What is Mitotic Index?  01:30 How Mitotic Index Is Calculated   03:00 Tumor Heterogeneity   07:00 Mitotic Index and Prognosis   11:00 High vs. Low Mitotic Index   15:00 Biopsy and Treatment Decisions   19:00 Re-Biopsy Insights   21:00 Wrap-Up    Get to know Dr. Brooke Britton: https://www.dogcancer.com/people/brooke-britton-dvm-dacvim-oncology/  For more details, articles, podcast episodes, and quality education, go to the episode page: https://www.dogcancer.com/podcast/   Learn more about your ad choices. Visit megaphone.fm/adchoices

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/WHH865. CME/MOC/AAPA/IPCE credit will be available until January 5, 2026.Crafting Custom Care in CLL: Guidance on Upfront and Sequential Treatment Decisions With Targeted and Immune-Based Platforms In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and CLL Society. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, BeiGene, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/WHH865. CME/MOC/AAPA/IPCE credit will be available until January 5, 2026.Crafting Custom Care in CLL: Guidance on Upfront and Sequential Treatment Decisions With Targeted and Immune-Based Platforms In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and CLL Society. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, BeiGene, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/WHH865. CME/MOC/AAPA/IPCE credit will be available until January 5, 2026.Crafting Custom Care in CLL: Guidance on Upfront and Sequential Treatment Decisions With Targeted and Immune-Based Platforms In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and CLL Society. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, BeiGene, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/WHH865. CME/MOC/AAPA/IPCE credit will be available until January 5, 2026.Crafting Custom Care in CLL: Guidance on Upfront and Sequential Treatment Decisions With Targeted and Immune-Based Platforms In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and CLL Society. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, BeiGene, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/WHH865. CME/MOC/AAPA/IPCE credit will be available until January 5, 2026.Crafting Custom Care in CLL: Guidance on Upfront and Sequential Treatment Decisions With Targeted and Immune-Based Platforms In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and CLL Society. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, BeiGene, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/WHH865. CME/MOC/AAPA/IPCE credit will be available until January 5, 2026.Crafting Custom Care in CLL: Guidance on Upfront and Sequential Treatment Decisions With Targeted and Immune-Based Platforms In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and CLL Society. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, BeiGene, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/GZE865. CME/MOC credit will be available until December 21, 2025.Refining the First Strike Against EGFR-Mutated Advanced NSCLC: Personalizing Frontline Treatment Decisions Amid Increasing Complexity In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/GZE865. CME/MOC credit will be available until December 21, 2025.Refining the First Strike Against EGFR-Mutated Advanced NSCLC: Personalizing Frontline Treatment Decisions Amid Increasing Complexity In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/GZE865. CME/MOC credit will be available until December 21, 2025.Refining the First Strike Against EGFR-Mutated Advanced NSCLC: Personalizing Frontline Treatment Decisions Amid Increasing Complexity In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/GZE865. CME/MOC credit will be available until December 21, 2025.Refining the First Strike Against EGFR-Mutated Advanced NSCLC: Personalizing Frontline Treatment Decisions Amid Increasing Complexity In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/GZE865. CME/MOC credit will be available until December 21, 2025.Refining the First Strike Against EGFR-Mutated Advanced NSCLC: Personalizing Frontline Treatment Decisions Amid Increasing Complexity In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/GZE865. CME/MOC credit will be available until December 21, 2025.Refining the First Strike Against EGFR-Mutated Advanced NSCLC: Personalizing Frontline Treatment Decisions Amid Increasing Complexity In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/EEY865. CME/AAPA credit will be available until November 24, 2025.A New Script for SCD Care: Guidance on Patient-Centric Treatment Decisions With Innovative Therapeutics In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Sickle Cell Disease Association of America, Inc. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Agios Pharmaceuticals, Inc., and Novo Nordisk Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/EEY865. CME/AAPA credit will be available until November 24, 2025.A New Script for SCD Care: Guidance on Patient-Centric Treatment Decisions With Innovative Therapeutics In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Sickle Cell Disease Association of America, Inc. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Agios Pharmaceuticals, Inc., and Novo Nordisk Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/EEY865. CME/AAPA credit will be available until November 24, 2025.A New Script for SCD Care: Guidance on Patient-Centric Treatment Decisions With Innovative Therapeutics In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Sickle Cell Disease Association of America, Inc. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Agios Pharmaceuticals, Inc., and Novo Nordisk Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/EEY865. CME/AAPA credit will be available until November 24, 2025.A New Script for SCD Care: Guidance on Patient-Centric Treatment Decisions With Innovative Therapeutics In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Sickle Cell Disease Association of America, Inc. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Agios Pharmaceuticals, Inc., and Novo Nordisk Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/EEY865. CME/AAPA credit will be available until November 24, 2025.A New Script for SCD Care: Guidance on Patient-Centric Treatment Decisions With Innovative Therapeutics In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Sickle Cell Disease Association of America, Inc. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Agios Pharmaceuticals, Inc., and Novo Nordisk Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/EEY865. CME/AAPA credit will be available until November 24, 2025.A New Script for SCD Care: Guidance on Patient-Centric Treatment Decisions With Innovative Therapeutics In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Sickle Cell Disease Association of America, Inc. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Agios Pharmaceuticals, Inc., and Novo Nordisk Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/EEY865. CME/AAPA credit will be available until November 24, 2025.A New Script for SCD Care: Guidance on Patient-Centric Treatment Decisions With Innovative Therapeutics In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Sickle Cell Disease Association of America, Inc. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Agios Pharmaceuticals, Inc., and Novo Nordisk Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/EEY865. CME/AAPA credit will be available until November 24, 2025.A New Script for SCD Care: Guidance on Patient-Centric Treatment Decisions With Innovative Therapeutics In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Sickle Cell Disease Association of America, Inc. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Agios Pharmaceuticals, Inc., and Novo Nordisk Inc.Disclosure information is available at the beginning of the video presentation.

Artera: Personalizing Treatment Decisions in Prostate Cancer and Beyond With Waqas Haque, MD, MPH, and Trevor Royce, MD, MS, MPH, FASCO by i3 Health

In this podcast episode, Dr. Robert Whitfield, a seasoned oncologic surgeon, and Dr. Ran Goshen, CEO of N1X10, discuss the complexities of cancer treatment and the importance of personalized medicine. Dr. Whitfield shares his personal and professional experiences, emphasizing the need for clear communication and patient-centered care. Dr. Goshen explains how his company uses genetic sequencing to tailor treatments to individual patients, highlighting a case where accurate diagnosis significantly altered treatment strategy. Dr. Whitfield and Dr. Goshen also highlight the vital role of patient advocacy in navigating cancer treatment, encouraging patients to be proactive and informed about their healthcare choices. Show Highlights: Discussion on Cancer as a Unique Disease (00:01:36) Cancer's complexity and the significance of personalized medicine Personal Genetic Material and Environmental Stressors (00:03:30) The impact of genetics and lifestyle on cancer expression Challenges in Health Care Systems (00:04:32) Misaligned incentives among healthcare stakeholders affecting patient care Rising Colorectal Cancer Rates in Young Patients (00:08:36) Increasing incidence of colorectal cancer in younger demographics Personal Experience with Family Cancer (00:09:23) Dr. Whitfield shares his personal losses due to cancer and its implications on treatment decisions. Patient Personalized Oncology Advocacy (00:11:41) Introducing a new approach focused on patient-centered cancer advocacy Planning and Intervention Phase (00:15:02) The process of planning and intervention in personalized oncology advocacy Importance of Patient Understanding (00:24:14) Emphasizing the need for clear communication with patients during their treatment journey Chemotherapy Response (00:27:40) Discussion on the unusual lack of response to chemotherapy in a specific ovarian cancer case Regret in Treatment Decisions (00:31:19) Dr. Goshen highlights the emotional burden of regret in cancer treatment decisions. Connect with Dr. Goshen: Website (https://n1x10.com/dr-ran-goshen/) info@n1x10.com (https://n1x10.com/dr-ran-goshen/#) Connect with Dr. Whitfield: Podcast (https://podcasts.apple.com/gb/podcast/breast-implant-illness/id1678143554) Spotify (https://open.spotify.com/show/1SPDripbluZKYsC0rwrBdb?si=23ea2cd9f6734667) TikTok (https://www.tiktok.com/@drrobertwhitfield?_t=8oQyjO25X5i&_r=1) IG (https://www.instagram.com/breastimplantillnessexpert/) FB (https://www.facebook.com/DrRobertWhitfield) Linkedin (https://www.linkedin.com/in/dr-robert-whitfield-md-50775b10/) X.com (https://x.com/rjwhitfield?lang=en) Read this article (https://www.breastcancer.org/treatment/surgery/breast-reconstruction/types/implant-reconstruction/illness/breast-implant-illness) Shop Dr. Whitfield's Solutions (https://drrobssolutions.com) SHARP (https://www.harp.health) NVISN Labs (https://nvisnlabs.com/) Get access to Dr. Rob's Favorite Products below: Danger Coffee (https://dangercoffee.com/pages/mold-free-coffee?ref=ztvhyjg) - Use our link for mold-free coffee. JASPR Air Purifier (https://jaspr.co/)- Use code DRROB for the Jaspr Air Purifier. Echo Water (https://echowater.com/)- Get high-quality water with our code DRROB10. BallancerPro (https://ballancerpro.com) - Use code DRROBVIP for the world's leader in lymphatic drainage technology. Ultrahuman (https://www.ultrahuman.com/ring/buy/us/?affiliateCode=drwhitfield)- Use code WHITFIELD10 for the most accurate wearable.

In this episode, two experts in the field of kidney cancer, Dr Benjamin Garmezy and Dr Vaishampayan, will present hypothetical case studies that represent typical patients seen with advanced renal cell carcinoma (aRCC) in practice. The faculty will discuss treatment approaches, adverse event management, and which factors to consider during the treatment decision-making process. Listeners to this vodcast audio, or views of the vodcast on the Oncology and Therapy website will get a better understanding of clinical trial outcomes related to an immuno-oncology (IO) agent and tyrosine kinase inhibitor (TKI) combination, such as axitinib plus pembrolizumab, that they can apply to their practice immediately. In addition, they will gain real-world insight into how experts approach the treatment of patients with aRCC and, more importantly, therapy management.   This podcast is published open access in Oncology and Therapy and is fully citeable. You can access the original published podcast article through the Oncology and Therapy website and by using this link: https://link.springer.com/article/10.1007/s40487-024-00305-3. All conflicts of interest can be found online. This podcast is intended for medical professionals.    Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.  

Please get your Human Design Chart before listening to this episode. https://www.emmadunwoody.com/get-your-chartCould your unique energetic blueprint hold the key to making better health decisions?Dr. Katie Deming is joined by Emma Dunwoody, a behavioral specialist and Human Design expert. This conversation offers practical insights on how to trust your inner authority and make choices that feel right for you.You'll discover the power of understanding your 'type' and 'strategy' - concepts that can help you navigate the confusing world of medical choices with more confidence and clarity. Chapters:04:22 - Why profiling tools face cognitive dissonance12:20 - I became the authority in my life19:59 - Learn your Human Design29:18 - Understand your body, make informed choices32:27 - Why Moving cities improved my mental healthEmma and Dr. Deming share real-life examples of how Human Design has helped people make empowered health decisions, sometimes even leading to remarkable healing outcomes. You'll learn why slowing down and tuning into your body's signals can make a real difference, especially when facing major health decisions.Listen and learn how your Human Design can transform the way you approach your health journey, especially when facing a serious diagnosis like cancer.This episode is a must listen if you have ever felt overwhelmed by medical advice that doesn't quite resonate with you. Send us a textI'd love your help in spreading the word about holistic healing. 1. Leave a review for Born to Heal on Apple Podcasts: 2. Take a screenshot of your review3. Share it on your Instagram Stories4. Tag me @the.conscious.oncologist5. And use the hashtag #BornToHealPodcastAs a thank you, you could win a one-on-one consultation with me, a Keto Mojo health tracking device, or a Komuso Shift necklace. Don't Face Cancer Alone"The 6 Pillars of Healing Cancer" workshop series provides you valuable insights and strategies to support your healing journey - Click Here to Enroll MORE FROM KATIE DEMING M.D. Free Guide - 3 Things You Need to Know About Cancer: https://www.katiedeming.com/cancer-101/6 Pillars of Healing Cancer Workshop Series - Click Here to EnrollWork with Dr. Katie: www.katiedeming.comFollow Dr. Katie Deming on Instagram: The.Conscious.Oncologist Take a Deeper Dive into Your Healing Journey: Dr. Katie Deming's Linkedin Here Please Support the Show Share this episode with a friend or family member Give a Review on Spotify Give a Review on Apple Podcast DISCLAIMER:The Born to Heal Podcast is intended for informational purposes only and is not a substitute for seeking professional medical advice, diagnosis, or treatment. Individual medical histories are unique; therefore, this episode should not be used to diagnose, treat, cure, or prevent any disease without consulting your healthcare provider.

Dr. Tim Richardson from Wichita Urology and Dr. Jonathan Henderson from Arkansas Urology discuss the use and benefits of Prolaris testing in prostate cancer management. Dr. Henderson elaborates on how Prolaris aids in decision-making for his prostate cancer patients, highlighting its role in reducing overtreatment and undertreatment. 

Investing continues to evolve and a new way some fiduciary financial advisors are charging for services could save you money. Know your options to make an informed choice for financial services. Also, before you sign up for expensive dental work, think twice & take Clark's advice. Flat Fee Financial Advisors: Segment 1 Ask Clark: Segment 2 Wisdom Teeth- AVOID Unnecessary Dental Work: Segment 3 Ask Clark: Segment 4 Mentioned on the show: Flat Fee Shops Attempt to Shake Up Financial Advising Advice-Only Network // Flat Fee Advisors 3 Places You Should Never Invest Your Money What Is a Fiduciary Financial Advisor and Do I Need One? How To Find and Choose a Financial Advisor What Is an HSA Account and How Does It Work? Target Date Funds: Clark's Favorite Retirement Investment How to Advocate for Yourself at the Dentist How getting a second opinion can stop you being ripped off — The Conversation Yes, your smart TV is spying on you – Here's how to stop it GM Stops Selling Driving Data to Insurance Companies How to Buy a New Car in 5 Steps Thank you for listening today, Clarkies! If you want to be part of our “Clarkie” segment, call 404-981-2071 to leave a comment or story. We may play it during a future episode! Clark.com resources Episode transcripts Community.Clark.com Clark.com daily money newsletter Consumer Action Center Free Helpline: 636-492-5275 Learn more about your ad choices: megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices

Phil discusses his diagnosis of diffuse aggressive B-cell non-Hodgkin's lymphoma and his reflections on dealing with cancer for the second time, emphasizing his attempts to put affairs in order and contemplate the significance of life and the possibility of an afterlife. Jackie shares her story of being diagnosed with leukemia at 17, undergoing a bone marrow transplant, and facing various long-term side effects and subsequent cancer diagnoses. The conversation also explores their attitudes towards treatment decisions, the importance of self-care, and the support they've received from their community. Throughout, both exhibit a strong sense of resilience, focusing on living in the present, the therapeutic value of creating art, and the idea of legacy and impact on others. 00:00 A Heartfelt Conversation on Cancer and Resilience 02:32 The Second Battle: Doubts and Reflections 13:35 Navigating Treatment Choices and Embracing Uncertainty 18:52 Exploring Faith and Spirituality Through Cancer Recovery 22:06 Reflecting on Life's Challenges and the Journey of Recovery 22:19 Embracing Retirement and Passing the Torch 23:33 The Essence of Recovery and Self-Care 27:22 Personal Growth and Future Aspirations 34:41 The Healing Power of Community Support and Spirituality 38:37 Navigating the Side Effects of Treatment and Embracing Change

On this episode of TMU we're diving deep into the rapidly evolving landscape of prostate cancer diagnosis and treatment with special guest, Dr. Adam Cole, a board-certified pathologist. Dr. Cole will discuss the traditional Gleason grading system, the limitations of pathology, and how incorporating genetic markers can improve patient outcomes.  Dr. Cole will touch on the importance of genetic testing in guiding treatment plans, and the potential use of artificial intelligence shaping the future of pathology.

In this episode, Nancy Reau, MD, and her patient discuss opportunities to optimize care for people living with hepatitis B virus and hepatitis delta virus, including:The importance of patient education along the care continuumEnsuring smooth transitions of care and communication between medical teamsScreening hepatitis delta in persons with chronic hepatitis BManaging hepatitis delta, including considerations for clinical trialsPromoting patient advocacyPresenter: Nancy Reau, MDProfessor of Medicine Chief, Section of HepatologyAssociate Director, Solid Organ TransplantationRichard B. Capps Chair of HepatologyRush University Medical CenterChicago, IllinoisContent based on an online CME program supported by an independent educational grant from Gilead Sciences, Inc.Link to full program: bit.ly/3SrMuGOGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

Check out this free downloadable resource and this podcast episode will give you more information on it. It's a quick reference guide to help you determine if someone's substance use is appropriate for you to work with or if they need a specialist. Today I'll walk through it and explain how it works.

A wet end to the growing season has created three main disease issues for growers.In this Pods for Profits, plant pathologist Marty Chilvers with Michigan State University will discuss how seed selection is a farmer's best line of defense for soybeans for next year. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

'Your Child, Your Choice: Vaccines & Treatment Decisions' with host Betsy Ashton, Dr. Pierre Kory and special guests, pediatricians Dr. Liz Mumper and Dr. Paul Thomas. Join us for this important discussion. Tonight, we are focusing on children, and the parents dilemma of how to decide which of the numerous vaccines in the CDC Schedule for children are necessary for their well-being, and is the schedule of shots causing problems? Watch and find out ------------------------------------------------------------- Formed by leading critical care specialists in March 2020, the Front Line COVID-19 Critical Care Alliance (FLCCC) has developed highly effective treatment protocols that aim to prevent and treat COVID-19 at all stages of the disease. We are a 100% donor-supported 501(c)(3) non-profit organization — our work would not be possible without you. Your gifts help us expand our reach and share the latest research available, for the health and well-being of all. To donate online, click here: https://covid19criticalcare.com/network-support/support-our-work/ To follow FLCCC, click here: https://covid19criticalcare.com/follow-flccc-2/ To learn more about our protocols click here https://covid19criticalcare.com/covid-19-protocols/ To register for weekly webinars, click here: https://geni.us/FLCCC_Webinar_Register To buy FLCCC gear, click here: https://supportflccc.store/ #115 (Aug. 02, 2023) Your Child, Your Choice: Vaccines & Treatment Decisions: FLCCC Weekly Update

The U.S. is in the midst of an ongoing prescription drug shortage with more and more medication in short supply for longer stretches of time. Those medications include chemotherapy drugs, antibiotics, ADHD medication and more. It's making treatment decisions difficult for doctors and patients. Laura Barrón-López discussed the shortages with Erin Fox. PBS NewsHour is supported by - https://www.pbs.org/newshour/about/funders

The U.S. is in the midst of an ongoing prescription drug shortage with more and more medication in short supply for longer stretches of time. Those medications include chemotherapy drugs, antibiotics, ADHD medication and more. It's making treatment decisions difficult for doctors and patients. Laura Barrón-López discussed the shortages with Erin Fox. PBS NewsHour is supported by - https://www.pbs.org/newshour/about/funders

Jeffrey Schussler, MD, FACC, FSCAI, Chief Medical Officer and an interventional cardiologist on the medical staff at Baylor Scott & White Heart and Vascular Hospital, provides information on cardiac computed tomography (CT) imaging studies to guide physicians when determining treatment decisions. In this podcast, Dr. Schussler discusses the types of studies available, the benefits of these studies and when to refer to an advanced center.

In this episode of Breast Cancer Conversations, Laura Carfang, founder of SurvivingBreastCancer.org, speaks with Janie Fielder a medical science liaison at Natara. The conversation centers around Signitera as well as genetic testing and the tools available for breast cancer patients to make informed decisions about their diagnosis and treatment plans. Fielder, previously a practicing nurse practitioner, manages a team of MSLs at Natara. The episode sheds light on the outstanding opportunities available to patients through Signitera, and the importance of informed decision-making in the breast cancer treatment process.Topics Covered Include:[00:02:21] Personalized cancer test. [00:04:30] Circulating tumor DNA. [00:09:08] Signetera's effectiveness in detecting CT DNA. [00:11:50] Biomarkers in breast cancer. [00:16:09] High-risk breast cancer. [00:19:50] Genetic mutations and breast cancer. [00:23:46] Genetic testing and breast cancer. [00:30:23] Medicare coverage for Signatura. [00:31:24] Breast Cancer Molecular Residual Disease.++++++++++++++++++++++++++++++++++About SurvivingBreastCancer.org. Survivingbreastcancer.org (SBC) was created in 2017 to help fill the gaps in breast cancer support, education, and resources. It was founded by Laura Carfang,  who was recently diagnosed at that time in her early 30's.  Since 2017, SBC has grown exponentially, serving members in the global breast cancer community.  Over these past few years, the SBC website has been visited by community members (over 1,000,000 page views) across 120+ plus countries, and Laura's podcast, Breast Cancer Conversations has been listened to in over 80 countries. Leveraging technology and breaking down barriers to access and information, SBC puts the patient first, educating, encouraging and inspiring advocacy.  Community members are encouraged to participate in the various free programming, events and services and are all invited to contribute to resolving the growing needs of this population. Website:https://www.survivingbreastcancer.org/Donate NowPlease consider making a donation.https://www.survivingbreastcancer.org/donate-nowSupport the show

Sometimes there are extenuating circumstances that make traditional treatment questionable for the newly diagnosed. Join Sarah and Beth as they talk to a Jamie, a newly diagnosed breast cancer patient about her concerns regarding treatment and why she opted not to do chemo or reconstruction after her doctor recommended it.

Drs John M. Kane and Christoph U. Correll discuss the importance of ongoing assessment of psychiatric comorbidities in patients with schizophrenia and its impact on outcomes and treatment decisions. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984483). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Schizophrenia https://www.medscape.com/resource/schizophrenia What Are the Major Metabolic and Neurologic Risks Associated With Antipsychotic Medications? https://www.medscape.com/viewarticle/969525 Trauma and Posttraumatic Stress Disorder (PTSD) in Patients With Schizophrenia or Schizoaffective Disorder https://pubmed.ncbi.nlm.nih.gov/19777347/ Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) https://www.psychiatry.org/psychiatrists/practice/dsm Relationship Between Obsessive Compulsive Symptomatology and Severity of Psychotic Symptoms in Schizophrenia: Meta-analysis and Meta-Regression Analysis https://pubmed.ncbi.nlm.nih.gov/36549240/ Clozapine-Induced Obsessive-Compulsive Symptoms: Mechanisms and Treatment https://pubmed.ncbi.nlm.nih.gov/30565908/ The Specific Phenotype of Depression in Recent Onset Schizophrenia Spectrum Disorders: A Symptom Profile and Network Comparison to Recent Onset Major Depressive Disorder Without Psychotic Features https://pubmed.ncbi.nlm.nih.gov/34942537/ Schizophrenia Comorbid With Panic Disorder: Evidence for Distinct Cognitive Profiles https://pubmed.ncbi.nlm.nih.gov/22417926/ Obsessive-Compulsive Disorder Comorbid With Schizophrenia and Bipolar Disorder https://pubmed.ncbi.nlm.nih.gov/30745688/ Depressive Symptoms in Schizophrenic Patients https://pubmed.ncbi.nlm.nih.gov/22112362/ Post-Psychotic Depression: An Updated Review of the Term and Clinical Implications https://pubmed.ncbi.nlm.nih.gov/35220306/ Mortality in People With Schizophrenia: A Systematic Review and Meta-analysis of Relative Risk and Aggravating or Attenuating Factors https://pubmed.ncbi.nlm.nih.gov/35524619/ Comorbid Major Depressive Disorder in Schizophrenia: A Systematic Review and Meta-Analysis https://pubmed.ncbi.nlm.nih.gov/33252130/ The RAISE Early Treatment Program for First-Episode Psychosis: Background, Rationale, and Study Design https://pubmed.ncbi.nlm.nih.gov/25830446/ First Episode Psychosis With and Without the Use of Cannabis and Synthetic Cannabinoids: Psychopathology, Global Functioning and Suicidal Ideation and Antipsychotic Effectiveness https://pubmed.ncbi.nlm.nih.gov/36682093/ Cannabis Use Among Patients With Psychotic Disorders https://pubmed.ncbi.nlm.nih.gov/35348056/ Methamphetamine Psychosis: Epidemiology and Management https://pubmed.ncbi.nlm.nih.gov/25373627/ Demographic and Clinical Correlates of Substance Use Disorders in First Episode Psychosis https://pubmed.ncbi.nlm.nih.gov/28697856/ Why Do Patients With Schizophrenia Smoke? https://pubmed.ncbi.nlm.nih.gov/20051860

Go online to PeerView.com/AQF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Late-onset Alzheimer's disease (LOAD) has a substantial genetic component, with heritability estimated to be between 40% and 80%, and the APOE ε4 allele is the strongest individual genetic risk factor for LOAD. Until recently, the APOE genotype test has been primarily used as a research tool and not recommended for clinical use. However, with the recent advances in disease-modifying therapies (DMTs), including several anti–amyloid monoclonal antibodies approved or in late-stage development, it is more important to determine which patients have the APOE ε4 allele and whether these patients are at an elevated risk of developing amyloid-related imaging abnormalities (ARIA). In this activity, based on a recent live webcast, experts examine the significance of APOE ε4 carrier status on the risk for developing LOAD, as well as the potential implications for patient care, including the increased risk for ARIA in patients taking anti-amyloid monoclonal antibodies. They provide guidance on identifying patients who may be candidates for genetic risk testing and share their best practices for interpreting and disclosing APOE test results and providing appropriate genetic counseling to patients and their families. Upon completion of this activity, participants should be better able to: Recognize the significance of APOE ε4 carrier status on the risk for late-onset Alzheimer's disease (LOAD) and the potential implications for patient care; Identify patients who may be candidates for genetic risk testing, and provide guidance on the benefits and limitations of direct-to-consumer testing versus genetic testing that is performed in a healthcare setting; and Interpret and share genetic risk test results with patients and their families in a clear, understandable manner, and tailor genetic counseling services to individual patients' needs in consultation with other members of the healthcare team.

Go online to PeerView.com/AQF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Late-onset Alzheimer's disease (LOAD) has a substantial genetic component, with heritability estimated to be between 40% and 80%, and the APOE ε4 allele is the strongest individual genetic risk factor for LOAD. Until recently, the APOE genotype test has been primarily used as a research tool and not recommended for clinical use. However, with the recent advances in disease-modifying therapies (DMTs), including several anti–amyloid monoclonal antibodies approved or in late-stage development, it is more important to determine which patients have the APOE ε4 allele and whether these patients are at an elevated risk of developing amyloid-related imaging abnormalities (ARIA). In this activity, based on a recent live webcast, experts examine the significance of APOE ε4 carrier status on the risk for developing LOAD, as well as the potential implications for patient care, including the increased risk for ARIA in patients taking anti-amyloid monoclonal antibodies. They provide guidance on identifying patients who may be candidates for genetic risk testing and share their best practices for interpreting and disclosing APOE test results and providing appropriate genetic counseling to patients and their families. Upon completion of this activity, participants should be better able to: Recognize the significance of APOE ε4 carrier status on the risk for late-onset Alzheimer's disease (LOAD) and the potential implications for patient care; Identify patients who may be candidates for genetic risk testing, and provide guidance on the benefits and limitations of direct-to-consumer testing versus genetic testing that is performed in a healthcare setting; and Interpret and share genetic risk test results with patients and their families in a clear, understandable manner, and tailor genetic counseling services to individual patients' needs in consultation with other members of the healthcare team.

Go online to PeerView.com/AQF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Late-onset Alzheimer's disease (LOAD) has a substantial genetic component, with heritability estimated to be between 40% and 80%, and the APOE ε4 allele is the strongest individual genetic risk factor for LOAD. Until recently, the APOE genotype test has been primarily used as a research tool and not recommended for clinical use. However, with the recent advances in disease-modifying therapies (DMTs), including several anti–amyloid monoclonal antibodies approved or in late-stage development, it is more important to determine which patients have the APOE ε4 allele and whether these patients are at an elevated risk of developing amyloid-related imaging abnormalities (ARIA). In this activity, based on a recent live webcast, experts examine the significance of APOE ε4 carrier status on the risk for developing LOAD, as well as the potential implications for patient care, including the increased risk for ARIA in patients taking anti-amyloid monoclonal antibodies. They provide guidance on identifying patients who may be candidates for genetic risk testing and share their best practices for interpreting and disclosing APOE test results and providing appropriate genetic counseling to patients and their families. Upon completion of this activity, participants should be better able to: Recognize the significance of APOE ε4 carrier status on the risk for late-onset Alzheimer's disease (LOAD) and the potential implications for patient care; Identify patients who may be candidates for genetic risk testing, and provide guidance on the benefits and limitations of direct-to-consumer testing versus genetic testing that is performed in a healthcare setting; and Interpret and share genetic risk test results with patients and their families in a clear, understandable manner, and tailor genetic counseling services to individual patients' needs in consultation with other members of the healthcare team.

Go online to PeerView.com/AQF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Late-onset Alzheimer's disease (LOAD) has a substantial genetic component, with heritability estimated to be between 40% and 80%, and the APOE ε4 allele is the strongest individual genetic risk factor for LOAD. Until recently, the APOE genotype test has been primarily used as a research tool and not recommended for clinical use. However, with the recent advances in disease-modifying therapies (DMTs), including several anti–amyloid monoclonal antibodies approved or in late-stage development, it is more important to determine which patients have the APOE ε4 allele and whether these patients are at an elevated risk of developing amyloid-related imaging abnormalities (ARIA). In this activity, based on a recent live webcast, experts examine the significance of APOE ε4 carrier status on the risk for developing LOAD, as well as the potential implications for patient care, including the increased risk for ARIA in patients taking anti-amyloid monoclonal antibodies. They provide guidance on identifying patients who may be candidates for genetic risk testing and share their best practices for interpreting and disclosing APOE test results and providing appropriate genetic counseling to patients and their families. Upon completion of this activity, participants should be better able to: Recognize the significance of APOE ε4 carrier status on the risk for late-onset Alzheimer's disease (LOAD) and the potential implications for patient care; Identify patients who may be candidates for genetic risk testing, and provide guidance on the benefits and limitations of direct-to-consumer testing versus genetic testing that is performed in a healthcare setting; and Interpret and share genetic risk test results with patients and their families in a clear, understandable manner, and tailor genetic counseling services to individual patients' needs in consultation with other members of the healthcare team.

Go online to PeerView.com/AQF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Late-onset Alzheimer's disease (LOAD) has a substantial genetic component, with heritability estimated to be between 40% and 80%, and the APOE ε4 allele is the strongest individual genetic risk factor for LOAD. Until recently, the APOE genotype test has been primarily used as a research tool and not recommended for clinical use. However, with the recent advances in disease-modifying therapies (DMTs), including several anti–amyloid monoclonal antibodies approved or in late-stage development, it is more important to determine which patients have the APOE ε4 allele and whether these patients are at an elevated risk of developing amyloid-related imaging abnormalities (ARIA). In this activity, based on a recent live webcast, experts examine the significance of APOE ε4 carrier status on the risk for developing LOAD, as well as the potential implications for patient care, including the increased risk for ARIA in patients taking anti-amyloid monoclonal antibodies. They provide guidance on identifying patients who may be candidates for genetic risk testing and share their best practices for interpreting and disclosing APOE test results and providing appropriate genetic counseling to patients and their families. Upon completion of this activity, participants should be better able to: Recognize the significance of APOE ε4 carrier status on the risk for late-onset Alzheimer's disease (LOAD) and the potential implications for patient care; Identify patients who may be candidates for genetic risk testing, and provide guidance on the benefits and limitations of direct-to-consumer testing versus genetic testing that is performed in a healthcare setting; and Interpret and share genetic risk test results with patients and their families in a clear, understandable manner, and tailor genetic counseling services to individual patients' needs in consultation with other members of the healthcare team.

This episode focuses on making treatment decisions when you or your loved one has been diagnosed with an advanced cancer. There are a lot of issues that a person has to navigate - financial concerns, legal documents, communicating with the care team, and the emotions that come with caring for a loved one with an advanced cancer diagnosis. With us today is hospice and palliative medicine physician Dr. BJ Miller.

This episode focuses on making treatment decisions when you or your loved one has been diagnosed with an advanced cancer. There are a lot of issues that a person has to navigate - financial concerns, legal documents, communicating with the care team, and the emotions that come with caring for a loved one with an advanced cancer diagnosis. With us today is hospice and palliative medicine physician Dr. BJ Miller.

When it comes to managing adults with HBV, should age factor into your treatment decision—or is it important to treat everyone, regardless of age?Listen as Dr George Lau discusses these questions and more for strategizing the monitoring and treatment of older adults with HBV. Presenter: George Lau, MBBS (HKU), MD (HKU), FRCP (Edin, Lond), FAASLD (USA)ChairmanHumanity and Health Medical GroupHong Kong, ChinaChair, Professor, and Co-DirectorLiver Diseases & Transplant CentreThe Fifth Medical Centre of Chinese PLA General HospitalBeijing, ChinaLink to full program:https://bit.ly/3fg9fwB